医学
宫颈癌
根治性子宫切除术
侵入性外科
子宫切除术
临床终点
危险系数
开放手术
癌症
外科
腹腔镜检查
根治性手术
随机对照试验
临床试验
总体生存率
置信区间
内科学
作者
Pedro T. Ramirez,Kristy Robledo,Michael Frumovitz,René Pareja,Reitan Ribeiro,Aldo López,Xiaojian Yan,David Isla,Renato Moretti‐Marques,Marcus Q. Bernardini,Val Gebski,Rebecca Asher,Vanessa Behan,Robert L. Coleman,Andreas Obermair
摘要
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The aim of this study was to compare overall survival between open and minimally invasive radical hysterectomy with participants followed for 4.5 years. The primary objective was to evaluate whether minimally invasive surgery was noninferior in disease-free survival (DFS) to abdominal radical hysterectomy. Secondary outcomes included overall survival. Sample size was based on DFS of 90% at 4.5 years and 7.2% noninferiority margin for minimally invasive surgery. A total of 631 patients were enrolled: 319 assigned to minimally invasive and 312 to open surgery. Of these, 289 (90.6%) patients underwent minimally invasive surgery and 274 (87.8%) patients open surgery. At 4.5 years, DFS was 85.0% in the minimally invasive group and 96% in the open group (difference of –11.1; 95% CI, –15.8 to –6.3; P = .95 for noninferiority). Minimally invasive surgery was associated with lower rate of DFS compared with open surgery (hazard ratio [HR], 3.91 [95% CI, 2.02 to 7.58]; P < .001). Rate of overall survival at 4.5 years was 90.6% versus 96.2% for the minimally invasive and open surgery groups, respectively (HR for death of any cause = 2.71 [95% CI, 1.32 to 5.59]; P = .007). Given higher recurrence rate and worse overall survival with minimally invasive surgery, an open approach should be standard of care.
科研通智能强力驱动
Strongly Powered by AbleSci AI